08:58 AM EDT, 07/21/2025 (MT Newswires) -- ProMIS Neurosciences ( PMN ) said Monday that the US Food and Drug Administration granted Fast Track designation to its lead candidate PMN310 for treating Alzheimer's disease.

The designation supports expedited development for therapies targeting serious conditions with unmet needs, the company said.

PMN310 is being evaluated in a phase 1b study for early-stage Alzheimer's, with interim data expected in Q2 2026 and final results in Q4 2026, ProMIS Neurosciences ( PMN ) said.

The company's shares were up nearly 150% in recent Monday premarket activity.